Por Renan Filho · 2026-10-16**Lead**
A wave of peer-reviewed studies published over the past year has confirmed that highly sensitive blood tests can identify molecular signs of Alzheimer's disease with accuracy rivaling expensive brain scans and invasive spinal taps. Researchers at leading U.S. institutions, including the National Institutes of Health and academic medical centers, now view these biomarkers as a critical tool for catching the disease in its earliest, most treatable stages — long before memory loss or cognitive decline becomes apparent.
**Context**
Alzheimer's disease, the most common form of dementia, affects an estimated 6.7 million Americans, according to the Alzheimer's Association. For decades, definitive diagnosis required either a lumbar puncture to measure amyloid and tau proteins in cerebrospinal fluid or a positron emission tomography (PET) scan — procedures that are costly, invasive, or not widely available outside major research hospitals. The search for a simple, scalable blood test has been a holy grail of neurology.
Recent advances in mass spectrometry and immunoassay technology have changed that picture. Several large-scale validation studies, including work from the Alzheimer's Disease Neuroimaging Initiative and the Swedish BioFINDER cohort, have demonstrated that measuring specific forms of phosphorylated tau (p-tau217 and p-tau181) in blood plasma can predict the presence of amyloid plaques in the brain with over 90% accuracy. These findings have been replicated in diverse populations across the United States, from rural clinics to urban academic centers.
In parallel, commercial laboratories such as Quest Diagnostics and Labcorp have begun offering Alzheimer's blood tests under strict clinical guidelines. The tests are not yet approved by the Food and Drug Administration for general screening, but they are available as laboratory-developed tests for use by specialists. The Centers for Medicare & Medicaid Services is currently evaluating coverage policies, a step that could dramatically expand access.
**Análise**
The implications of a reliable blood test for Alzheimer's extend far beyond individual diagnosis. Clinical trials for new therapies have long been hampered by the difficulty of enrolling patients in the earliest stages of the disease, when interventions are most likely to succeed. A simple blood draw could screen thousands of potential participants quickly and cheaply, accelerating the development of drugs that target amyloid, tau, and other pathological mechanisms.
Moreover, early detection allows patients and families to plan for the future, access support services, and participate in lifestyle interventions that may slow progression. The Alzheimer's Association has emphasized that a positive blood test should always be confirmed by a specialist and accompanied by comprehensive counseling, given the psychological weight of a diagnosis with no cure.
Critics caution that widespread screening without clear treatment pathways could lead to overdiagnosis and unnecessary anxiety. The tests are not perfect — false positives and false negatives occur, particularly in people with other medical conditions or in racial and ethnic groups underrepresented in validation studies. Researchers are actively working to improve accuracy across diverse populations, including African American and Hispanic communities, which have higher rates of Alzheimer's but have historically been excluded from biomarker research.
**Fontes**
- Alzheimer's Association. “2024 Alzheimer's Disease Facts and Figures.” - National Institute on Aging, National Institutes of Health. “Blood Tests for Alzheimer's: What You Need to Know.” - Palmqvist, S., et al. “Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders.” *JAMA*, 2020. - Hansson, O., et al. “Blood biomarkers for Alzheimer's disease in clinical practice and trials.” *Nature Medicine*, 2023. - Quest Diagnostics. “AD-Detect Test for Alzheimer's Disease Risk.” - Labcorp. “Plasma Amyloid and Tau Biomarker Test.”